Good morning, ladies and gentlemen, and welcome to the Jounce Therapeutics Fourth Quarter and the Full Year 2018 Earnings Conference Call. (Operator Instructions) As a reminder, this conference call is being recorded at the company's request.
Thank you, operator. Good morning, and welcome to the Jounce Therapeutics Fourth Quarter and Full Year 2018 Financial Results Conference Call. This morning we issued a press release which outlines the topics that we plan to discuss today. The release is available in the Investors and Media section of our website at www.jouncetx.com.
Speaking on today's call will be our CEO and President, Dr. Rich Murray, who will discuss our pipeline progress and key milestones for 2019; followed by our CMO, Dr. Beth Tréhu, who will provide an update on the clinical and preclinical development activities; lastly, our CFO, Kim Drapkin, will review our full year 2018 financials and review our 2019 financial guidance. We will then open the call for your questions.
Before we begin, I would like to remind everyone that today's discussion will include statements about our future expectations, plans and prospects that constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including the risk factors discussed in our SEC filings.
In addition, any forward-looking statements represent our views only as of today, March 6, 2019, and should not be relied upon as representing our views as of any subsequent date. While we may elect to update these forward-looking statements at some point in the future, we specifically disclaim any obligation to do so even if our views change.
Thanks, Komal, and good morning, everyone. 2018 was an important year for Jounce. We accomplished several key milestones, 2 of which centered around our most advanced product candidate, vopratelimab or vopra, formally JTX-2011, our ICOS agonist.
We reported several data readouts from the ICONIC trial at ASCO and SITC, which demonstrated important insights into vpora's mechanism of action and strong scientific rationale for the next stage of clinical development.
As we recently announced, we will present 3 posters at the upcoming AACR Annual Meeting, which will include an important validation of our ICOS biomarker, demonstrating improved progression free survival and overall survival in patients with the biomarker.
Using our Translational Science Platform, we analyzed clinical and biomarker data to develop new scientifically driven clinical trial designs, based on rational combination strategy and new potential predictive biomarkers. We began enrollment of safety dose escalation combination cohorts with ipilimumab and with pembrolizumab in June 2018. And today, we're pleased to announce that we've established safety in combination with both, thus, supporting new Phase II studies.
We also continued to advance our broader pipeline of first-in-class immunotherapies. In early 2018, we announced the advancement of our first tumor-associated macrophage candidate, JTX-8064 into IND-enabling studies. JTX-8064 targets LILRB2, also known as ILT4, a macrophage target, which we see as analogous to a macrophage checkpoint. JTX-8064 represents an example of our vision to discover new therapies and pathways that involve multiple immune cell types, and we're excited by the data we've seen so far. We look forward to providing more information about JTX-8064 in a poster at the AACR Annual Meeting in a few weeks.
We also advanced our JTX-4014, our PD-1 inhibitor, into Phase I clinical trials and completed enrollment in the first cohort in the fourth quarter of 2018. As previously stated, we believe combination therapy will be the mainstay of cancer immunotherapy, and that PD-1 checkpoint inhibitors, like JTX-4014, will play an important role in combination with our future product candidates.
We hope to transform the treatment of cancer and provide long-lasting benefit to patients and believe more than ever that success at immuno-oncology will likely come from a highly scientific and reverse translational approach.
On that note, let me highlight what we believe to be 3 key elements of this approach, and later on, Beth will give you direct examples of each. First and foremost, is to identify the right patients. Early in the development process, we used our Translational Science Platform to evaluate multiple potential predictive biomarkers. More importantly, once clinical and biomarker data are available from the clinical trial, we then use our platform to identify the unique characteristics of the mechanism of action in any association with responding versus nonresponding patients.
Second, we believe it is necessary to move beyond the PD-1 inhibitor-centric approach. Our focus is on combinations with a strong scientific rationale, irrespective of whether they include a PD-1 inhibitor.
Third, it's critical to address the unmet need in tumors that did not have T cells. Some of these tumors, which may either be cold or dominated by immunosuppressive macrophages, do not respond well to T cell directed immunotherapies. We're building a diverse pipeline targeting multiple immune cell types, including immunosuppressive macrophages, T Regulatory cells and stromal targets. Our approach in pipeline address all 3 of these important elements.
In January, our partner, Celgene, announced an agreement under which Celgene may be acquired by Bristol-Myers Squibb. As a reminder, in 2016, we received a nonrefundable upfront payment of $225 million and an equity investment of $36.1 million from Celgene.
Child's funds conducts and leads all activities prior to any partner opted. Celgene continues to be a great partner for us, and assuming the BMS Celgene acquisition closes as planned, we look forward to continue to working with BMS. We understand that there is overlap in our lead clinical programs and BMS's pipeline, but regardless, we see any outcome as having positive consequences for Jounce. We'll either have a strong partner in the IO field in BMS or we will retain a 100% of the worldwide rights for any unauctioned program and have the opportunity to advance it on our own or potentially with the new partner.
I'd like to know turn the call over to Beth to discuss our pipeline and science in more detail. Beth?
Thanks, Rich, and good morning, everyone. This is an exciting time for Jounce as we translate important learnings from our preclinical analyses and clinical trials into clinical progress. Our reverse translational work has provided us with a strong scientific rationale for future trials, and I am pleased to provide an update on our progress from 2018 and our plans going into 2019.
I'd like to start with vopra and the ICONIC trial. In the Phase I/II ICONIC trial, tumor reductions were associated with an ICOS pharmacodynamic biomarker, specifically emergence in the peripheral blood of a population of ICOS high CD4 T cells, which have the characteristics of activated CD4 T Effector cells. This pharmacodynamic biomarker has been critical in interpretation of our clinical data and in informing the next set of phase II studies for vopra. We have shown that emergence of these activated CD4 T Effector cells is due to vopra and not PD-1 inhibitors.
In a few weeks, at AACR, we will present 2 posters on vopra, one providing more details about the characteristics of these cells, and one providing clinical data showing improved progression free and overall survival in ICONIC patients who have emergence of these cells. In separate analyses, we have demonstrated that vopra only activates CD4 T cells if they express high levels of ICOS. The relationship between the emergence of ICOS high CD4 T cells and clinical benefits and the requirement for these cells to be present for vopra activity has led to 2 development paths. First, since CTLA-4 inhabitation has been shown to induce the population of ICOS high cells in the peripheral blood, while PD-1 inhibitors do not, there is strong scientific rationale for the ongoing clinical development of vopra in combination with ipilimumab. Based on this important reverse translational work, we will be initiating New Phase II studies this year of vopra in combination with the ipilimumab in both non-small cell lung cancer and bladder cancer. The second path is based on patient selection for new predictive biomarkers that may enrich for patients who are more likely to benefit. We have identified candidate predictive biomarkers through a comprehensive analysis of baseline blood and tumor samples from the subset of patients treated in the ICONIC trial, with an emphasis on understanding the differences between the baseline characteristics of responders, all with emergence of ICOS high CD4 T cells and nonresponders in whom these cells did not emerge. We believe that applying our platform to reverse translational analysis of clinical trial data to inform our patient selection strategy is more relevant than relying on preclinical data.
As mentioned at AACR, the vopra clinical data being presented shows that ICONIC patients with emergence of ICOS high CD4 T cells have improved progression free and overall survival. This finding further validates the role of this ICOS pharmacodynamic biomarker in directing the next stage of the clinical development strategy for vopra. We plan to initiate the new Phase II studies in 2019 with preliminary efficacy data expected in 2019.
I would now like to turn to our next first-in-class program, JTX-8064, which targets tumor-associated immunosuppressive macrophages. At Jounce, we believe that targeting different immune cell types may allow us to develop innovative therapies for tumor types that are not responsive to T cell directed therapies alone. Our goal is to convert the immunosuppressive tumor micro environment to an immune activating antitumor environment, which is likely to require targeting multiple cell types.
When LILRB2, the target of JTX-8064, binds to its ligands, an immunosuppressive state is created. Similar to other immune checkpoints such as PD-1 and CTLA-4, LILRB2's ligands may also be an immune evasion strategy employed by tumors. By inhibiting the binding of LILRB2 to its ligands, we hope to release the brakes on this immunosuppressive interaction, resulting in a reprogramming of the macrophages from the immunosuppressive or M2 phenotype to immunostimulatory or M1 phenotype. We believe this is analogous to a macrophage checkpoint.
As mentioned, in just a few weeks at AACR, we will also present a poster on JTX-8064, that will describe the preclinical evaluation of this exciting product candidate and its role in reprogramming tumor associated macrophages within the tumor micro environment. We expect to file the IND and initiate a Phase I study of JTX-8064 later this year and look forward to updating you on our continued progress.
Finally, I'd like to touch on our PD-1 inhibitor, JTX-4014, for which we remain on track to identify the recommended Phase II dose later this year. In today's update, I hope that we have conveyed the unique way in which Jounce approaches development of first-in-class immunotherapies, applying our Translational Science Platform to incorporation of pharmacodynamic and potential predictive biomarkers from early preclinical through clinical development and to reverse translational analysis of clinical data to inform continued clinical development.
Now I would like to turn the call over to Kim for a discussion of our full year 2018 financial results and review of our 2019 guidance. Kim?
Thanks, Beth, and good morning, everyone. As we reported in this morning's press release, we ended 2018 with cash, cash equivalents and investments totaling a $195.9 million compared to $257.9 million for 2017. This is in line with our 2018 financial guidance of a $185 million to $195 million. The decrease in cash was due to increased operating costs incurred during the year offset by the receipt of state and federal income tax refunds.
Turning to the P&L. Our collaboration revenue was $65.2 million for the full year 2018 compared to $71.6 million for 2017. Recall that collaboration revenue, currently noncash, reflects the recognition of the Celgene upfront payment received in July 2016.
During 2018, we incurred $70.1 million in research and development expenses compared to $67.8 million in 2017. The increase in R&D expenses for the full year 2018 was due to $3.1 million of increased employee compensation costs and $3 million of increased external clinical and regulatory costs, offset by $2.1 million of decreased external R&D costs and $2 million of decreased lab consumables purchases.
General and administrative expenses were $26.4 million for 2018 compared to $23.1 million for 2017. The increase in G&A expenses is primarily the result of increased employee compensation costs.
Net loss for 2018 was $27.4 million or a net loss per basic and diluted share of $0.84 as compared to a net loss of $16.4 million for 2017 or a net loss per basic and diluted share of $0.57. This increase is driven by a decrease in noncash collaboration revenue and an increase in operating expenses.
We reiterate the 2019 financial guidance we provided in January. We continue to expect cash burn on operating expenses and capital expenditures for the full year 2019 to be approximately $80 million to $95 million. We also continue to expect noncash collaboration revenues of approximately $50 million to $60 million.
Our strong balance sheet allows us the flexibility to drive our innovative immunotherapy pipeline, plus efficiently execute against our strategic plans and goals. Based on our current operating plans, we expect our existing cash, cash equivalents and investments will be sufficient to enable us to fund our operating expenses and capital expenditure requirements for at least the next 24 months.
Thanks, Kim. Before opening the call to your questions, I'd like to reiterate that 2019 will be focused on advancing our pipeline as we report important and incremental data and execute on our anticipated milestones. Importantly, we are well capitalized to drive our development candidates and bring additional new programs forward. We built a strong culture with a team of dedicated and talented professionals who remain focused on discovering and developing innovative therapies that bring durable benefits to cancer patients. As such, we have a lot coming up this year for our 3-lead development candidates and our discovery pipeline.
To reiterate, we plan to: report updated PFS and OS data from the ICONIC trial of vopra at AACR; initiate new Phase II studies of vopra; establish safety, tolerability and the recommended Phase II dose of JTX-4014; file the IND and initiate Phase I of JTX-8064; and continue to work on advancing our next development candidates into IND-enabling studies.
With that, we'd like to now open the call for your questions. Operator?
(Operator Instructions) And our first question comes from Cory Kasimov of JPMorgan.
This is Carmen on for Cory. So for 4014, I apologize if I missed this, when might we be able to get a first look at the data from the ongoing trial? Is that something you would present when you make the decision to select a dose to take to Phase II?
This is Beth. So given that it's a Phase I dose escalation, we would like to move into Phase II as quickly as possible. And I'm not sure at this point then when we'll decide to disclose the Phase I data. We may wait and just present Phase II data, but we haven't disclosed that right now.
Okay. And then for 2011, I just wanted to clarify, you mentioned kind of 2 potential path forward. One, combination like ipi and lung and bladder, and then the second path was just identifying patients more likely to benefit. Would that be kind of a tumor-agnostic approach? Or how are you thinking about that, if you could provide more details?
Sure, I'll comment on that. That's Rich -- this is Rich speaking. Yes, we -- with the combination with ipi, we've got through the indications, and we've got a lot of work done with KOLs and our internal science and technology committee as to indications, landing on small cell and better. In the predictive biomarker space, we're certainly looking in a manner that could be tumor agnostic. We think that there is the potential for the immune system, of course as it cuts across indications, to offer those types of opportunities to find the right patients. So that's the direction we would head. But more details on that later.
And our next question comes from Boris Peaker of Cowen.
My first question is as you noted the observation of peripheral T cells associated with vopra activity. I'm just curious, is that something that could be used as a biomarker to monitor the efficacy of the drug shortly upon starting of treatment?
Yes, that's a good question, Boris. I think it has multiple potential uses, so it's certainly something that we can monitor on treatment, particularly for combining with other agents, such as ipi, we can monitor the degree to which we see these cells. After ipi, after vopra, it gives us a good way to look at other potential drugs that we could combine with vopra with a similar strategy, but importantly, it also then allows us to start looking for potential predictive biomarkers that can help us identify the patients in whom those cells may emerge. But yes, it certainly can be a good tool, and potentially looking at it in real time can give the investigators a sense of whether to keep their patients unsteady or not.
Got you. And a second question on the biomarker. You've, obviously, done a lot of work on ICOS biomarker. I'm just curious, do you feel confident that you have derived at what a clear definition of ICOS high is? Or is that threshold still kind of evolving moving target.
Yes, I'll take that one, Boris. Yes, so from the data that we've seen, we do see a -- associated with vopra, we do see a clear pattern of emergence, it's a robust population that emerges. So we have set criteria and conditions around kind of how this assay is run and have validated that for all the purposes that Beth went through. So we feel comfortable that -- I mean, the convenience of it being in the blood and not the tumor is obvious as well, but we feel confident that when we see that positive -- kind of that positive population, it really is positive. I'll add maybe one kind of note that helps also to frame the kind of tight association of benefit in biomarker is, we have seen and reported at SITC and there'll be more at -- upcoming at AACR. We have seen in patients that have kind of achieved a stable disease state, when those patients lose the population of cells then the patients progress. So there is the kind of continued maintenance of the cell population and the long durable responses, and then there is this relatively kind of tight association of having the cells and losing the cells in correlation with then progressive disease.
Got you. And lastly, just on the biomarker. Is it possible that this biomarker, and what you just mentioned about losing these cells, is kind of indicative of overall immune health, and so you would expect it to just decline with progression of disease as the cancer kind of defeats the immune system? How do we know the kind of the prospective versus just correlative properties of the biomarker?
Sure. So as we've presented at SITC, we did a separate study where we looked at 77 patients who were receiving either PD-1 or PD-L1 inhibitors, and we did intensive profiling of their peripheral blood and did not find it in any of those patients on treatment with a PD-1 inhibitor, including 6 patients who had confirmed responses. So if it were just a marker of immune cell health, we think we would have seen it in at least some of those patients, particularly in the responding patients, but we did not see it. And that's consistent with the biology with PD-1 inhibitors being more active than CD8 cells really than on CD4 cells. And it's also something that we've seen emerge on treatment, although, as you heard, we do think we have ways to maybe find out which patients may have some of those primed or high ICOS size cells at the beginning using a predicted biomarker, but in all the work we've done, it does appear to be something that's directly associated with vopra.
And our next question comes from Jim Birchenough, Wells Fargo.
I guess the first question is just in terms of the ipi inducing ICOS high CD4 response, have you looked at that in the safety study that you've done with vopra? And just interested, do you have any insights into the time course of how long does it take for ipi to induce that ICOS high state?
Sure. Yes, we're definitely looking at that in the dose escalation studies, the safety study with vopra and ipi. Most of the data on the kinetics of its emergence or its induction by ipi come from the literature from publications by Pam Sharma, Jeff Weber, others who have shown kind of the timing, and it generally appears during the first 1 or 2 cycles of ipi therapy.
And then just on that combination, Beth, with ipi, one of the things that's struck us from the ICONIC results is if you could dose vopra long enough you see to get some benefit. How has that gone in terms of in combination with ipi? Can you dose the 2 drugs long enough to get the expected results?
Yes, so we're not really sharing the data from the dose escalation at this point, but as Rich mentioned, we do have a tolerable safety profile, with vopra and ipi. And it supports moving forward to the next phase of the study. So that's something we'll obviously be monitoring, but as I mentioned earlier, being able to give the investigators feedback on whether those cells are emerging and other biomarker data, we think will be helpful in helping to maintain patients on treatment long enough to benefit. And Rich, do you want to add anything?
Yes. And Jim, I think another angle on that is also as we move to lines of therapy in patient populations as opposed to being in the relapse refractory population, it'll be kind of the healthier patient population, if you will, that we think could track to being able to stay on therapy long enough for these immune mechanisms to kick in.
And then just -- finally, just trying to tie the biology in altogether. If you look at patients that have the peripheral ICOS high CD4 cells, have you looked at whether those CD4 cells are infiltrating the tumor? And I guess the second part of the question is just looking at the PFS and OS data will get at AACR, should we also look for tumor response data, not necessarily resist response, but just stable disease or tumor shrinkage as an important metric as well?
Yes, I'll take the first one, and then Beth can comment on the last part of that question. So yes, at the -- we've got 2 posters at AACR with vopra. One would be the clinical data, the PFS and the OS, Beth will pick up on that, but then also we will have a more mechanistic poster looking at the characterization of these cells, we continue to find them to have all the characteristics that one would expect for kind of a cycling activated T Effector cell. And in addition, we will be kind of tracking various means, the periphery as well as tumor locations of the cells, kind of tracking them in different ways. I can't say too much more before the -- before that comes out, but would refer you to the abstract, which is published on our second vopra JTX-2011.
Yes, and then with respect to your question about responses. So yes, there is updated data particularly on the durability of the responses that we've previously reported, and we've had them centrally reviewed now. But I think what we feel is the most compelling, really, getting to the core by immunotherapy still exciting, is really the durability and the PFS and OS that we're seeing in correlation with the biomarker. But there will be obviously more data than just that. And we'll also be digging into the characteristics of the patients, so that you kind of see what the baseline characteristics of these patients are, and then that will help you put the data in context.
Yes, that links into to the earlier question about kind of the tumor agnostic potential.
And our next question comes from Mike Ulz of Robert W. Baird.
Maybe you can just talk about the current status of the ongoing Phase I dose escalation for the JTX-2011 combinations? And if you can maybe your current thinking in terms of the go-forward dose for Phase II, just based on the press release, it sounds like you may be considering some different schedule there?
Yes. So as you know, the dose escalations started in June, and we have determined the dose to take forward in the new studies that's safe and well tolerated. And yes, we're not providing a lot of details, but yes, we do feel that some changes in the dosing schedule make sense based on the biology, and we'll be providing more details about them in the future.
Yes, a part of that, Mike, is that we are looking kind of back to the kinetics and how to -- how we think we could optimally kind of create that lower threshold for priming from the ipi dose and then come in for the expansion of these population of cells with vopra.
And our next question comes from Debjit Chattopadhyay from H.C. Wainwright.
So just to clarify, the requirement for this particular phenotype -- detail phenotype, was that implemented in the ipi combo initiated in June of 2018? Or this is something that's getting implemented in -- for all future studies?
Yes, so just following up on that, in terms of the expression of this phenotype, are there specific tumor types that you would think that this is likely to show up in -- or are these your traditional ipi sensitive tumors? And also in terms of the prior lines of therapy that these patients have had, does that make a difference in ipi's ability to induce this. And the other one would be in terms of just looking at your current data set, what percent of patients actually have this biomarker -- predictive biomarker?
So we're -- in terms of the -- more details about the predictive biomarkers, we're not prepared to disclose a lot of information on that. We looked at these ICOS high CD4 T cells in a subset of patients, and what we've shown is data from about 50 patients in the study, and in that group, all the people who had tumor reductions had emergence of this cell type and the people who did not, didn't. And it was present in 18 of the 50 patients who actually had emergence of it. So in terms of the induction of these cells, Pam Sharma has shown it in several different tumor types, it's been demonstrated in bladder cancer, which is obviously important since that's one of the tumors we're going into. It's also been shown in melanoma, and in very small series it's been shown another tumor types, so we don't think this is particularly a tumor-specific phenomenon. And I think -- did I answer all of your question? Is there more to it?
Oh, yes, yes. Thank you. Yes, thank you. Well, actually what's really interesting from our ICONIC data is that we saw tumor reductions and durable stable disease in some non-small cell lung cancer patients who had failed PD-1 inhibitors and had emergence of these cells. And this -- the patients in our study were also very heavily pretreated, but we'll actually be providing specifics about that lines of therapy, prior -- types of prior therapies and more patient baseline and characteristics and their relationship to the emergence of these cells in the poster at AACR. So hope you'll come by and see the poster, I think you'll get a lot more information from that.
Yes. Just a quick follow up on the bladder (inaudible) we are expanding into, would this primarily be PD-1 low -- and I'm obviously (inaudible) in eligible patients?
Go ahead. I just had one more follow-up.
Yes. So as you know, that's a growing unmet need. As the PD-1 inhibitors move into earlier lines of therapy, the PD-1 experienced patient population is now one for whom there is not really a standard of care. And so it provides -- it's an opportunity for us to address a large unmet need, but also the point Rich made before, we think by moving into these less heavily pretreated patient population we'll be treating patients who are little healthier, able to remain on study longer, and hopefully, reap the benefits of the immunotherapy combination that we're treating them with.
Yes, maybe just one other point on that related to the non-small cell lung cancer. What we did see, and again, more details at AACR, in fact, PD-1 experienced patients who showed benefit as well as induction of the cell population from non-small cell lung cancer. So we're looking at the mechanism, if you will, of the ipi and CTLA-4 and ICOS as a mechanism that's not necessarily dependent on PD-1.
Great. And one last one for me. Are you hearing anything from your investigators regarding the GSK program, and differentiation versus yours in terms of strategy and what they might have seen with the GSK stuff, which obviously seems to be gaining some traction as well?
We don't try to get that kind of information from our investigators. Yes, so we only know what GSK has said publicly, and we know that they're actually putting a lot of investment into their ICOS program and are very excited about it. And to date, we haven't seen anything that leads us to think that there's a big difference in terms of what they are seeing clinically, but we -- it's really hard to tell because they haven't presented that much information.
Yes, we're anticipating information from GSK later this year I think at ESMO.
Yes, yes. Second half of the year.
(Operator Instructions) And our next question comes from Steven Seedhouse of Raymond James.
You mentioned the upcoming AACR presentation will show improved PFS and OS in the ICOS high T cell patients, can you just clarify what that is in relation to historical controls or to the non-ICOS high patients?
Yes, it's looking at the ICOS high versus the ICOS low patients.
And -- yes, and also looking at the overall study population.
Okay. And then just trying to understand the biology of this biomarker. Have you identified a patient ever in ICONIC or in the archived samples that you've looked at from CTLA-4 treated patients, where the actual T cell -- the ICOS high T cell Corporation itself was present before treatment?
From the published data, there -- I am not aware of any data suggesting the ability to detect these cells in the peripheral blood prior to treatment.
And one -- Steve, maybe I could add a comment on that, I think one thing that -- or at least the way we're thinking about the biology here is that, wouldn't necessarily be kind of unusual if there was an expanded population in a patient or a person, it could be from a influenza vaccine or the variety of reasons why you could have expanded populations. But we think the key there is particularly in the ipi combination is if ipi is lowering the thresholds for kind of new priming events, which hopefully would include tumor-specific T cells, it's then that kind of next sequence of how do you quickly expand that population of cells that could hopefully get to the tumor. So that's kind of the way we're looking at the biology. We haven't seen and nor had there been published reports of preexisting, but that's obviously something we'll continue to look at.
Okay. And just lastly, again, on the biomarker. Were of the CTLA-4 treated patients that you looked at complete responders? And if so, does the biomarker persist -- or would the biology suggest it might persist in a patient with a durable complete response?
Yes. So I'm not sure what you mean in terms of the CTLA-4 patients that we've looked at, but in the literature that was one of the things that got us interested in ICOS at the very beginning, when Pam Sharma showed data that showed that induction of ICOS high CD4 cells correlated with improved survival. But really importantly and this gets to what Rich was saying earlier about the stable disease patient, you had to have persistence of those cells. And we know that at some point after you stop ipi, which can't be given indefinitely, you do start to lose those cells, whereas with JTX-2011 -- sorry, vopra being so far in our hands very safe, it's something that you can keep giving and maintain that population of cells.
And that concludes our question-and-answer session for today. Ladies and gentlemen, thank you for participating in today's conference. This does conclude the program, and you may all now disconnect. Everyone, have a great day.


text:
Verbal Abuse in Relationships
Verbal Abuse Videos
Disorders Resulting from Abuse
Healing After Abuse
Leaving Abuse
Signs and Symptoms of Abuse
Stop Abuse
About Verbal Abuse in Relationships Authors
Cold Verbal Abuse and Calculated Betrayal
January 3, 2019 Kristen Milstead
Cold abuse, verbal abuse delivered without emotion, is familiar to many abuse victims. The film I, Tonya, depicts the physically and verbally abusive home life of notorious Olympic skater Tonya Harding. Harding is best known for the scandal that took place in 1994 in which her husband, Jeff, carried out a plot to maim Nancy Kerrigan, her skating rival, prior to the winter Olympics that year. There is a scene in the film in which the teenaged Harding sits at the dining room table eating breakfast with her mother. She has a black eye, given to her by Jeff, her boyfriend at the time.
Harding's mother tells her that her makeup doesn't cover the abuse and remarks in an off-handed way, "You're a dumb piece of s*** who thinks she deserves to get hit."
Harding continues to eat and responds under her breath, "How'd I get that idea?"
"Maybe he should hit you," her mother responds, calmly and unemotionally. "Maybe you'd learn to keep your big mouth shut. Sure helps me out."
The film is difficult to watch. It illustrates all of the methods of delivery of verbal abuse that I have discussed previously, including angry or hot abuse, covert abuse, and cold abuse, which this scene illustrates.
I know and remember this form of verbal abuse well, for it is the one that hurt the most. Sometimes, as in this scene from the film, my boyfriend delivered his comments completely emotionlessly. Other times, it was delivered with a look of smugness on his face, as if he was receiving pleasure from the pain he was inflicting on me.
What made it cold abuse to me, however, as I reflect back, is that "cold" seemed precisely how he felt. It was as if he had gone completely dead inside. His calmness was almost inhuman, and he acted as though he felt absolutely nothing for me, except maybe hate.
Why Cold Verbal Abuse Hurts So Much
We live in a culture where verbal abuse is rampant. Any stranger on the street can yell demeaning comments at us and engage in hot abuse. Even turning on the news can provide us with the latest YouTube videos of customers abusing store clerks over policies they don't like or the latest Twitter wars between celebrities and public figures. The social distance threshold for abusive people to take aim and attack is almost unlimited.
Covert verbal abuse is more subtle. Because it allows the abuser to cause harm but avoid responsibility, it can take place in environments where there is more of a relationship between the two parties but the abuser has a greater investment in keeping the abuse hidden, such as in the workplace.
Both hot abuse and covert abuse can also occur in more intimate relationships, such as in families or in romantic relationships. What makes cold abuse different, however, is that it works only in relationships where there is a high degree of emotional investment. You will not find it in relationships among strangers or acquaintances, or at work.
Abusers who use their cold demeanor to deliver their verbally abusive comments understand that the pain comes from the complete betrayal of the relationship through their indifference to that pain.
These abusers need you to love them so they can rip it away with their callousness.
Verbal abuse does not have to look "out of control" or come from a place of perceived anger in order to cause emotional violence.
In I, Tonya, we don't see Harding's mom provide her with much affection. In my relationship, however, these moments of cold abuse stung so much because they were such a sharp contrast to the way he had formerly treated me with such love.
When he smiled and said things to me such as, "You were just a piece of meat to me," I couldn't dismiss what he'd said as merely an emotional outburst, because he hadn't had one. In fact, he'd outright enjoyed what he'd said to me at times like that.
Not only was it as if everything he had ever said to me when he'd been good to me was a lie, but it was also as if the very person he'd presented to me before had been a lie too.
It was one of the most violent things he ever did to me.
Tags: cold verbal abuse
Milstead, K. (2019, January 3). Cold Verbal Abuse and Calculated Betrayal, HealthyPlace. Retrieved on 2019, July 19 from https://www.healthyplace.com/blogs/verbalabuseinrelationships/2019/1/cold-verbal-abuse-and-calculated-betrayal
Author: Kristen Milstead
Kristen is a survivor of narcissistic abuse. She has a Ph.D. in Sociology and is the author of a toolkit, "Taking Your Life Back After a Relationship with a Narcissist," which is available for free on her website, Fairy Tale Shadows, a blog with the mission of promoting awareness about hidden abuse and empowering other survivors. Find Kristen on Pinterest, Facebook, Twitter, Instagram and on her website.
How to Recognize Covert Verbal Abuse
Victim Blaming: 5 Reasons Why Verbal Abuse is Not Your Fault
Things Verbal Abusers Say and Do
After Emotional Abuse: Do the Side-Effects Ever Disappear?
Are You in Love with Your Abuser? If So, There's a Reason
Co-Parenting With An Abuser
Leaving An Abusive Relationship: Why Can't I Just Leave?

redpajama_set_name: RedPajamaCommonCrawl


Poonch, May 31: A ration dealer was arrested today on charges of black marketing rice meant for public distribution in Poonch district of Jammu and Kashmir.
Acting on a specific information, a police team headed by SHO Surankote under the supervision of SSP Poonch raided a private shop at Dani Dhara Gunthal village in Surankote and arrested the dealer.
He was involved in selling the government rice in the open market, Station House Officer (SHO) Surankote Mohd Anzar Mir said.
100 bags of rice, each weighing 50 kg, were seized on the spot, the officer said.
The officer said that a case under relevant sections of law has been registered and further investigations were taken up.


text:
Queer Poetry to Pay the Rent
By Melanie Camp
It started as an experiment. Brian Sonia-Wallace wanted to see if he could pay his rent through poetry. From here, his journey as Rent Poet began.
Working with numerous social justice and arts non-profits since college, in 2014, the poet found himself in between jobs.
"I was at a point where I was looking to take a just minimum wage job," he said, holding him over until something more substantial came along.
However, after doing the math on California minimum wage and comparing what he'd earn working a retail job versus busking on a street corner as a poet with a typewriter, he decided to hit the streets.
Initially, those in the poetry community thought Sonia-Wallace was crazy.
"It was actually funny, I went to different poetry venues, and I talked about what I was doing, and all the poets rolled their eyes and were like, 'yeah good luck with that.'"
Those who did support Sonia-Wallace's artistic endeavor were the least likely.
"The bankers and real estate people were like, 'this is fantastic! Can we pay you to come to do poems at our events' and the poets were like, 'yeah, you'll never make money like that,'" he said.
Sonia-Wallace describes himself as falling into a weird space somewhere between a Capitalist and a Marxist.
"In the sense of thinking about art as labor," he said explaining, "we have this idea that art is a great thing for kids and self-expression and therapy and those are all sorts of personal pursuits," for which we don't expect to be paid.
Whether he sets up on a street corner or at an event full of investment bankers, his job as Rent Poet is always the same. He asks a couple questions: Who the poem is for, and what is the subject? Then, after 10 minutes or so, tapping on his typewriter, he crafts a one-of-a-kind poem.
The poet believes poetry is a tool that "has a lot of potential to connect to people." Quoting Lawrence Ferlinghetti, "Poetry is the shortest distance between two people," Sonia-Wallace agrees poems are, in a way, like spells. "I do think people, in a relatively secular age, come to poetry for things that they would have gone to a shaman or a witch or a potion maker for," he said.
There are limits on what Sonia-Wallace will write as Rent Poet. He once turned down a man who asked him to write something to help win back an ex-girlfriend.
"There's a bit of neuroscience that says when we hear a story our brains are patterning themselves in the same way that the person remembering and telling that story's brain is patterned. Which is just like the neuroscience of empathy. If you are telling someone a story or a poem, it is as if you are making their brain be your brain for a moment," said the poet.
After a couple of years as Rent Poet, in 2016, Sonia-Wallace published his first book, "I Sold These Poems, Now I Want Them Back." inspired by his experience as a poet for hire. His role as Rent Poet has landed Sonia-Wallace in a series of unlikely writer residencies. One with Amtrack, another on the road as a poet in residence for a political campaign in Tennessee. In another, Sonia-Wallace found via Facebook, the poet set up his typewriter and wrote poems at the Mall of America in Minnesota.
The Mall of America gig led to a New York Times article, which led to Sonia-Wallace getting a second book deal through Harper Collins. That book is due for release next year, 2020.
"I've just done all of these very Americana poetry adventures," said Sonia-Wallace and this is what the book is centered around.
For Pride month, the poet is staying closer to home. As part of the City of West Hollywood's One City One Pride LGBTQ Festival, throughout June, Sonia-Wallace is running Everyone Deserves (A) Love (Poem), a Pride poet pop-up interactive installation where queer poets armed with typewriters will set up on the streets of West Hollywood and type you a poem.
City of West Hollywood Arts Coordinator, Mike Che, told The Pride LA the pop-up is "an interactive art project where anyone can get a love poem written for them or someone they love, in celebration of this year's One City One Pride theme; Love is Love."
On May 22 – Harvey Milk Day – Sonia-Wallace and team of typewriter poets worked the first installation to kick-off One City One Pride.
"Everyone who received a poem left with a smile on their face, which is I think the best thing this project could accomplish," said Che.
As Sonia -Wallace said, "words are how we record our thoughts and put them in other people's heads."
That is the power of a poem.
Get a poem at the Dyke March on June 7 from 6pm-9pm. Also, the One City One Pride booth at Pride on the Boulevard, June 8 and 9, from 12pm-7pm will host a Pride poet pop-up. Plus, the poets will be typing at the Day of Art event on June 30 from 1:30pm-7:30pm
For last-minute pop-up notifications and exact locations, follow @rentpoet and @WeHoArts on Instagram.
Listen to the Beautiful Hollywood Podcast with Melanie Camp and hear Rent Poet share his story here: anchor.fm/beautiful-hollywood/episodes/Rent-Poet-e3t2pf
By thepridela June 11, 2019
Tags: bi, Brian Sonia-Wallace, City of West Hollywood, gay, Gender, LA Pride, LGBT, LGBTQ, lgbtqia_, Michael che, One City One Pride, poem, poet, Poetry, Pop Up, Pride, typewriter, weho, west hollywood, write in A&E, ARTS, BEST OF GAY LA, BOOKS, CALENDAR, FEATURED, FEATURES, LOCAL, LOS ANGELES, VENICE, WEST HOLLYWOOD, WEST LA
BOOKS, BUSINESS, LGBTQ+, LOCAL, WEST HOLLYWOOD
January 14, 2021 Timothy Michael
The City Council of the City of West Hollywood approved an item to submit a request to rename the West...
ARTS, LGBTQ+, LOCAL, LOS ANGELES
The Los Angeles LGBT Center has been awarded a $100,000 grant from the S. Mark Taper Foundation to support the...
Photo by Chris Rodriguez
BUSINESS, COVID-19, LGBTQ+, LOCAL, NIGHTLIFE
Oil Can Harry's, the iconic and beloved gay country western line dancing bar, located in Studio City, is closed for...
COVID-19, HEALTH, LGBTQ+, LOCAL
The first of 400 doses received by the Center were dispensed by Dr. Ward Carpenter, co-director of health services at...
ARTS, LGBTQ+, LOCAL, WEST HOLLYWOOD
The City of West Hollywood has announced three $5,000 grant awards, totaling $15,000, for three resident artists for its 2021...
BUSINESS, COVID-19, LGBTQ+, LOCAL, NIGHTLIFE, SILVERLAKE
Saving Silver Lake Bar Akbar
Struggling to survive amid the Corona-virus pandemic, iconic LGBTQI+ hangout Akbar took to a fundraising page to ask for help....
ARTS, LGBTQ+, POETRY, VIDEO, WRITING
The "After the Music" video animates a poem written especially for the holiday season by West Hollywood City Poet Laureate...
ARTS, LGBTQ+, LOCAL, POETRY, WEST HOLLYWOOD, WRITING
Brian Sonia-Wallace has been named West Hollywood's 4th City Poet Laureate making him the youngest person to occupy the role. ...


Join SugarDaddyForMe.com and find the perfect sugar daddy in Worcester, MA.
Join SugarDaddyForMe.com and find the perfect sugar baby in Worcester, MA.
Seeking or Need Sugardaddy Worcester - Why HePays?
fastest growing sugar baby school in the country. And while it claimed there was "
rich men chat with beautiful women from Worcester, Hereford and Worcester.


text:
Q: Converting NSImage to NSData I get NSImage like that:
imageG = [[[NSImage alloc] initWithSize:NSMakeSize(imageN.size.width, imageN.size.height)] autorelease];
[imageG addRepresentation:[NSCIImageRep imageRepWithCIImage:result]];

And the result is really good. So there are no mistakes i think. And then I try to convert this image to NSData like that:
 NSData *imgData = [imageG TIFFRepresentation];

And i am getting error:
Thread 1: EXC_BAD_ACCESS (code=13, adress=0x0)

at that line. Where is my mistake?

A: You need to retain your object as you create it, it appears it's being reallocated by the time you ask it for its data reorientation.
imageG = [[[[NSImage alloc] initWithSize:NSMakeSize(imageN.size.width, imageN.size.height)] retain] autorelease];
Generally if you create an object from an initializer - not a factory method - you should retain and auto release it. The benefits of doing so, and other good tips on memory management can be found at: Why should a self-implemented getter retain and autorelease the returned object?
It's also to handy to note that BAD_ACCESS indicates a memory issue of some kind.

redpajama_set_name: RedPajamaStackExchange


Are the correct areas of the premises covered?
Is the system documentation correct and available?
Has the system been designed for the correct emergency duration period?
Is a completion certificate available with photometric design data?
Is a test log available and are the entries up to date?


After posting a pic of store bought Chinese chicken noodle soup last week on facebook, a few people asked us if we would have a similar recipe we could share.
So here it is, our version of Chinese chicken noodle soup. It's very easy to make and is perfect for a quick mid-week winter meal that the whole family will enjoy!
1. Cook the noodles according to the packet instructions and set aside.
2. Simmer the stock with chicken, ginger strips, garlic, baby corn and soy sauce for 3-5 minutes or until the chicken is cooked through.
3. Add the bok choi and simmer for a further minute or until just tender.
4. Divide the noodles and mushrooms between 4 bowls and ladle the stock, chicken and vegetables over the top.
5. Garnish with bean sprouts, shallots, coriander and chilli. Serve immediately.
Tip: This soup can also be made with beef, just substitute the chicken stock for beef stock, and the chicken breast for beef strips.


text:
Q: Error while creating C++ array #include "connection.h"

 ConnectionType[] ConnectionArray = new ConnectionType[NUMBER_OF_CONNECTIONS];

I get 2 errors

*

*Error: expected an identifier

*Error: expected a ';'

I have
class ConnectionType {
public:
  Ptr<Socket> txMstrSocPtr; /// Pointer to Master tx socket
  Ptr<Socket> rxMstrSocPtr; /// Pointer to Master rx socket
  Ptr<Socket> txSlavSocPtr; /// Pointer to Slave tx socket
  Ptr<Socket> rxSlavSocPtr; /// Pointer to Slave rx socket

  //ConnectionType();
  //~ConnectionType();

  void rxMstrCallBack(Ptr<Socket> socket);
  void rxSlavCallBack(Ptr<Socket> socket);
};

Defined in connection.h

Do you have any idea why I get these 2 errors?

A: The declaration syntax needs to be changed to:
ConnectionType* ConnectionArray = new ConnectionType[NUMBER_OF_CONNECTIONS];


text:
Set during a period of peak tensions between North and South Korea in the 1980s, Squid Game star Lee Jung-jae's directorial debut is an electrifying espionage thriller.
After a high-ranking North Korean official requests asylum, KCIA Foreign Unit chief Park Pyong-ho and Domestic Unit chief Kim Jung-do are tasked with uncovering a North Korean spy, known as Donglim, who is deeply embedded within their agency.
When the spy begins leaking top secret intel that could jeopardize national security,
the two units are each assigned to investigate each other. In this tense situation where if they cannot find the mole, they may be accused themselves, Pyong-ho and Jung-do slowly start to uncover the truth. In the end, they must deal with an unthinkable plot to assassinate the South Korean president. Then begins a terrible race against time. The situation of the two Koreas is on the verge of implosion and the two agents, during their investigation, will unearth heavy secrets that threaten to overturn the history of the country.
Login to add to watchlist
Cast your vote and rate this movie for the Liuna! People's Choice Award.
Chrysler St. Clair Centre
Fri Nov 4
Capitol Pentastar Theatre
Sun Nov 6


text:
zielony szlak "kaszubskiej marszruty
Green Trail of "the Kashubian Route"
The main motive of the trail are the attractions associated with the rivers and lakes connected by streams localized near the routes that decorate the landscape of the eastern border of the Zaborski Landscape Park.
The route from Mylof to Chojnice guarantees additional architectural attractions of the biggest city in the region, as well as villages near Powalki.
Distance of the trail: 41.8 km
The time it takes to cover the tour: 5-6 hours
Trail difficulty: Medium
Chojnice – (3.8 km) Klawkowo – (7.2 km) Powalki – (10.4 km) Klodawka – (16.0 km) Mylof – (18.0 km) Okreglik – (20.7 km) Gieldon – (25.0 km) Czarniz – (28.8 km) Kinice – (30.3 km) Kosobudy – (33.6 km) Brusy – (37.0 km) Zabno – (41.8 km) Mecikal
0 km – Chojnice. The old city with a medieval layout of the 13th century. Basilica of the 14th century. Baroque Jesuit college with a church of the 18th century. Neo-Gothic town hall from 1902. city walls with towers and Gate Czluchowska of the 14th century, recreational areas in the Park Millennium .
Chojnice – district city with a population of 40 000 residents, due to the location called "Gate of Pomerania". The first mention of the town dates from 1275. Shortly after the occupation of Pomerania by the Teutonic Knights in 1309. Chojnice was given its city rights. On September 18, 1454 took place the first battle of the Thirteen Years' War. After the occupation of Poland, there was a 200-year period of development of the city; in the 16th century flourished the Reformation. The period of prosperity ended in the mid-17th century. From the late 19th century the town began to grow again in 1871 was set up the railway line Ostbahn Berlin – Königsberg. On 31 January 1920 under the provisions of the Treaty of Versailles the Polish army entered Chojnice. In 1939 Germans carried out mass executions in the so-called Death Valley, located in the Municipal Forest. On February 4, 1945 Chojnice was invaded by the Soviet army, as a result 45% of downtown was found in ruins. After the war, the city expanded to several new residential and industrial districts. The Basilica of the Beheading of St. John the Baptist, made of brick, was built between 1340 to 1360 in the Gothic Vistula style; during the years 1903-1906 a stately neo-Gothic portal was built and added to it. It stands next to old parsonage, which can be considered to be the oldest dwelling house in Chojnice. The baroque church of the Annunciation of St. Virgin Mary was built by the Jesuits in the years 1733 to 1744 as part of the complex, which included a convent and college; inside preserved late Baroque decor with polychrome and illusionist dome. Alongside stands the building of the Jesuit College built in the years 1744-1755. The former church and convent of Augustinian current buildings were built in the late Baroque style in the years 1786-1794. City Hall located in the middle of the market was built between 1901-1903 on the site of the previous one from the 14th century. Built of red brick neo-Gothic façade of a Modernist decor and stepped gable with pinnacles. The Old Town has preserved spatial arrangement typical for cities established on the Chelminskie law with checkered streets and a main square set in the middle. The architecture of the main town square suffered during the war in 1945. The remaining houses from the mid-nineteenth century have late Baroque classicism features. From the west and partly of the south and east Chojnice is surrounded by city walls. They were formed in the mid-14th century and had three gates (Mill, Czluchowska and Gdansk) and 22 towers, some of which have survived to this day. Czluchowska gate was built in the first half of the 14th century; now it houses the seat of the Museum of History and Ethnography. We're going Warszawska street and Swietopelka street to Koscierska street on which runs highway No. 235 to Koscierzyna. On the outskirts of Chojnice there is a bike path on the right, which at the beginning of the town Klawkowo passes to the left. We're going through Klawkowo asphalt path and cross the railway Chojnice – Kościerzyna track and the intersection at Krojanty. A further route is marked by small villages Powalki and situated on the side Zbeniny.
7.2 km – Powalki. In the vicinity of Powalki in the villages of Czartolomie and Krojanty there are manor parks and palaces built in the 19th century and modernized in the 20th century.
8.3 km – Zbeniny – village mentioned in the years 1311-1317. Late-classical manor from 1857 was rebuilt in 1926 and is now in ruins. Behind the settlement Klodawka we enter the forest and leave a path along the highway, which runs further along the black trail to the village Mecikal. We turn to the local asphalt road that runs towards Mylof, just before the village we find the yellow trail from Czersk and follow it on a beaten road.
16.0 km – Mylof. A forest settlement on the Brda River built here in 1849 with a Poland's only stepped dam. It is piling Brda's waters at the height of 12 meters, powering hydroelectric power. At the dam begins the Great Brda Canal with its 21 km of length and previous irrigation of meadows around Czersk.
We pass the dam on Brda and part with the yellow trail, which runs to Mecikal. We go local asphalt road through the village Okreglik to another village called Gieldon. On the left you can see the lake Trzemeszno, we turn on the gravel road running towards the forester's house and a shrine. We drive a gravel road through the forest, past a settlement of blocks of the Forestry Gieldon. We reach asphalt road and ride it through the village Czarniz. At the end of the road we turn to the gravel road that runs along meadows by the river Niechwaszcz, there are rare species of plants and animals. We reach Kinice village, where there is asphalt, following the Glowna and Lesna streets we go toward Kosobudy village.
20.7 km – Gieldon. In the area there is the lake Trzemeszno combined with the stream of J. Kosobudno. A shallow lake Trzemeszno and adjacent beaches provide a good place to relax.
25.0 km – Czarniz. The village, with a rare phenomenon called bifurcation consisting of forking of the river Niechwaszcz for a few arms.
28.8 km – Kinice. A section of the trail between Kosobudy and Czarniz runs through wet meadows and valleys of the river Niechwaszcz, which is a habitat for many rare species of animals and plants.
30.3 km – Kosobudy. The village already existed in the 13th century. In 1330 the Teutonic Knights established the office of the mayor covering a substantial portion of the land Zaborska. Neo-Gothic church of the Sacred Heart of Jesus built by evangelicals in 1871. Opposite the church there is a long time parish house, in the village there are also preserved buildings from the late 19th century, and the statue of St. John of Nepomucen from 1925. The school has a Regional Chamber. We pass the church of the Sacred Heart of Jesus.
We encounter the red trail from Czersk, we follow it to Czerska street through Kosobudy. On the Nepomucena street there is a bike path on the right side of the road. We take it to Brusy.
33.6 km – Brusy. A town with a population of approx. 5 000 inhabitants is the center of the region Zaborow, inhabited by Zaborakowie, Krëbanowie people. The name Brusy comes from the word "brus" – a millstone. The village Brusy mentioned in 1324 was set on Chelmno law in 1351. Since 1466 it was a royal property. In the second half of the 19th century Brusy became the center of the Kashubian movement. After 1945 Brusy has grown considerably, and in 1988 it gained city rights. The most valuable monument of the town is the All the saints church. This neo-Romanesque church was designed by Adolf Dankert of Brandenburg in the years 1876 to 1879 with the initiative of Father Augustine Wiki-Czarnowski. Impressed by its size – 61 meters long, 26 meters wide and 12.5 meters high, it is one of the largest churches in Pomorskie. Inside there is a Baroque altarpiece "bracki" of the 17th century.
We reach the train station via Dworcowa street and Nad Dworcem street, further along the streets Ogrodowa, Targowa and Armii Krajowej we get to a roundabout. Here we leave the red trail running to Charzykowy. We're going through a paved bicycle path on the right side of the Gdanska street and leave Brusy. We pass Brusy-Wybudowanie, before the railway crossing move away from the provincial road to get back to it in Zabno. In here there have been preserved remains of late classicist mansion of the 19th century. A short piece of cobbled lanes we cross the line Chojnice – Koscierzyna, near the railway station Zabno near Chojnice we go deep into the forest, pass the cemetery of Soviet soldiers. We go now on a gravel path on the left side of the road No. 235 Koscierzyna – Chojnice. It brings us to the village Mecikal.
37.0 km – Zabno. In the past it was a village of a noble character, which resembles late-classical mansion with a landscaped park of the 19th century. The park of 1 ha you can admire the old trees, which include monumental linden trees, maples and oaks.
41.8 km – Mecikal. A village founded in the Middle Ages, near the ford at Brda river. During the war, the village was burned by the Germans, the villagers hid themselves near the lake Moczadlo. In Mecikal you can see the monument to the fallen partisans of the Pomeranian Griffin.
53.6944, 17.556925
km szlak zielony mapa
Zapora Mylof, fot. Pomorskie Travel
foto oznakowanie szlaku 6
foto na trasie 5
foto miejsce odpoczynku 2
foto kladka w męcikale 1
Chojnice ratusz, fot. Pomorskie Travel
forest 1973952 1920
f2097756ea5530934686620750003844 scaled
Distance — 0 M
Around the lake Charzykowskie
Distance — 206 M
The Człuchów Gate in Chojnice
The Museum of History and Ethnography in Chojnice
THE SUKIENNICE
TURYSTYCZNY
Discover the region
Kashubia
Slupsk land
Tuchola forest
Zulawy
Powisle
Bory Tucholskie Kashubia Tricity Tricity Slupsk land Kashubia Tuchola forest Kociewie Zulawy Powisle
Nature and relax
Water tavels
Aqua parks and swimming pools
Loop of Zulawy Waterroute
Health spa beauty
Tourist voucher / #RatujemyGastro
Landscape parks
Observation points
Zoo's and botanical gardens
Recreation and fun
National memorials
Coulinary prestige
Maritime culture
Opera, philharmonic, theatre
Squares and monuments
Sobieszewska Island in Gdańsk
Pomeranian Cycling Trails
Skis or snowboard? Only in Pomerania!
The Górki Zachodnie Harbour
Charzykowskie Lake
Sea sailing
How does Zbigniew Gutkowski sail?
Design and implementation: ın+uı
As part of our website, we use cookies to provide you with services at the highest level, including in a manner tailored to individual needs.
sing the website without changing the cookie settings means that they will be stored on your end device.
Unfortunately, you don't have any favorite items yet.
Add the item to your favorites by clicking on the heart icon.
Clear everything
Save to your favorites


text:
Forces broke my back, says slain youth's father
By Raashid Hassan on July 12, 2018 Comments Off on Forces broke my back, says slain youth's father
Shopian: Hordes of mourners are visiting the house of Khursheed Ahmad Khan at Vehil village to condole the killing of his 14-year-old son Tamseel Ahmad Khan.
Tamseel was killed by government forces in clashes during a gunfight in nearby Kundalan village on Tuesday, in which two JeM militants were also killed.
According to witnesses, Tamseel was shot on the forehead, some 600 meters away from the gunfight site in Kundalan village. They said he was going along with some people to Kundalan village when he was shot.
Tamseel was a Class 9 student at the government high school in Vehil. Outside, his house on Wednesday, as mourners line up, pictures of Tamseel and slain militants hung from the walls.
Tamseel's mother, Meema Banoo came out of house, with the support of two women and starting kissing the pictures.
"When would you come back as you told me that you will bring bread from market. They killed you on an empty stomach, come home I will give you my heart for meals," Meema wailed in front of the picture of her slain son.
"Government forces broke my already broken back," Tamseel's, father, Khursheed said. A carpenter by profession, Khursheed is suffering from a disc problem.
"Tamseel would handle chores at home after school hours. Despite my limited earnings, I spent all my earning to raise and educate my children to have support in old age but, they all of a sudden, killed my son, that too when he was hiding behind a tin wall to avoid the wrath of forces," he said, alleging that it was a targeted killing as his son was shot on forehead.
Tamseel's cousin Liyakat Ahmad told Kashmir Reader that he couldn't recognise his cousin till he removed identity card from his pocket.
"I saw him falling on ground, he was there in an orchard as the forces were withdrawing from encounter. One among the troops shot him as Tamseel tried to take refuge behind a tin wall," he said adding that till they reached Shopian he was not aware that he was carrying his cousin.
"He succumbed to his injuries near Nowgam bypass Srinagar, all I took him to hospital for was to clean the blood on his face and clothes," he said.
Family sources said that Khursheed was planning to shift to a newly built one-storey house which the family was managing to get completed.
"Before they could shift, their house saw crowds of mourners," an elderly villager remarked.
Villagers added that Khursheed was hardly able to meet two ends and Tamseel helped father with work at home and orchards.
Khursheed was on work at Gadapora village when, he said, he received a phone call around noon telling him that his son has been injured. "The family where I was working dropped me at home. Then I took a vehicle to go to Srinagar, the driver on reaching Meminder turned back. As I asked him why he turned back he went mute and I realised that my son is no more," he said.
On Tuesday morning, Khursheed said, he told his son to accompany him for spraying in apple orchard.
"He told me, the weather is not good today and an encounter is underway in Kundalan which was almost five kilometers away from our village. I choose to go for work then," Khursheed said while adding that he had no strength to work but was working only for his children.
AFSPA, CIVILIAN KILLINGS, Indian Army, Kashmir conflict, Kashmir issue, Kashmir killings, Modi Govt
Forces broke my back, says slain youth's father added by Raashid Hassan on July 12, 2018


text:
Hirome Ichiba, Much More than Just a Market
Naoya Fujii
Nate Hill Nov 30, 2011 - 4 min read
Greeted by a hearty, "Ohayo gozaimasu! (good morning)" by a friendly middle aged woman as she opens her shop, dodging the fishermen as they frantically unload the morning catch from their trucks, and still beingg a little shocked by the occasional elderly man having a pint of beer with breakfast, I realize, as I walk by most mornings, that Hirome Ichiba(market) is a pretty special place.
Hirome Ichiba is in downtown Kochi, near the castle. Opened in 1998, this very unique market was all about creating a tourist destination to spread the knowledge of Kochi's food, friendliness, and artistic culture.
In fact, Hirome comes from theJapanese verb hiromeru, meaning to propagate. The name was also chosen because Hirome Shigeaki, a popular minister to the lord of Tosa during the Tokugawa period, is said to have lived in the same spot.
Hirome (by the way, most locals drop the 'Ichiba') is made up of over 60 shops that fill this relatively small building. While the majority are izakaya's and restaurants, you can also find anything from fresh fish, to local produce, souvenirs, clothes and jewelry.
Large wooden tables with benches and stumps for seats are set out in a type of food court style, but is so much more than a food court. Hirome is all about friendliness and convenience. The open style allows people to get whatever food and drink they want, and sit anywhere that's open. Many times, groups that don't know each other will share a table and start talking as if they're old friends.
As a popular hang out for local expats, Hirome is also a good chance for the traveler to find someone who speaks English and learn a little bit more about life in Kochi.
I've met people from all over the world in Hirome, and it's always fun to hear about what brought them to Kochi. Whether it's surfing, the 88-temple pilgrimage, or just traveling around Japan, we always have a nice chat and part ways feeling happy to have connected to the shared experiences of another traveler. In some way or the other, it always feels as if you're just saying hello to a slightly different version of yourself.
Don't expect, though, that other foreigners are the only people you'll meet at Hirome. Keeping to the friendly spirit of Kochi, you will probably be approached by at least one fairly inebriated local. Depending on your ability to communicate in Japanese and theirs in English, the experience could range from quite enjoyable to painstakingly awkward. Regardless, it will probably make for a fun memory and add even more to the character of Hirome.
It's very easy to get to Hirome as it's downtown at the end of the covered arcade street, Obiyamachi. If you're meeting up with someone else in Kochi, it's a great meeting spot, especially if you can't agree on food and just want a place with a lot of cheap options.
If you're in the city on the last Saturday of of October, stop by after 11:30pm as there's a huge Halloween party that brings out the whole of the international and Japanese community alike. Similarly, there's a New Year's Eve count down party as well.
Hirome is a lot of fun regardless of when you go, so I hope you'll check it out as there is nothing else like this in Japan—Japanese tourist from other prefectures are usually blown away by this iconic display of Kochi spirit.
Find out more about Hirome Market.
Nate Hill @nate.hill
I've been living in Kochi since 2006. I enjoy taking every chance I can to ride my bicycle, camp, swim in rivers, relax on the beach, and explore the surrounding mountains -- all of which can easily be done in Kochi. We're out of the way, but worth it.I'd love to connect with you on Twitter @Koch...
2 Chome-3-1 Obiyamachi, Kochi, 780-0841 (Directions)
hirome.co.jp
By Nate Hill
Mephistopheles Cafe
Cafe Stanley
Kochi Castle Tour and History
Discover Kochi
Top 10 Things to Do in Kochi Prefecture, Japan
Top 5 Things to Do Around Kochi City, Japan
A Day at Katsurahama Beach
Anpanman Museum
Chikurin Temple in Kochi
Tengu Kogen
My You Bus
Mitamura Shoten Udon Bar & Izakaya
By Sebastian Schuster
By Emi Takahata
Mahatoma
By Sherilyn Siy
Plant-based Whopper Released at Burger King Japan
Explore Food around Japan